2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
F Andreotti, T Geisler, JP Collet, B Gigante… - European Heart …, 2023 - academic.oup.com
The first international guidance on antithrombotic therapy in the elderly came from the
European Society of Cardiology Working Group on Thrombosis in 2015. This same group …
European Society of Cardiology Working Group on Thrombosis in 2015. This same group …
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis
Background In randomised controlled trials, fixed-dose combination treatments (or polypills)
have been shown to reduce a composite of cardiovascular disease outcomes in primary …
have been shown to reduce a composite of cardiovascular disease outcomes in primary …
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Background A fixed-dose combination therapy (polypill strategy) has been proposed as an
approach to reduce the burden of cardiovascular disease, especially in low-income and …
approach to reduce the burden of cardiovascular disease, especially in low-income and …
Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations …
RE Schmieder, S Wassmann, HG Predel, B Weisser… - …, 2023 - Am Heart Assoc
Background: Single-pill combination improves adherence and persistence to medication in
hypertension. It remains unclear whether this also reduces cardiovascular outcomes and all …
hypertension. It remains unclear whether this also reduces cardiovascular outcomes and all …
Monoclonal antibodies to disrupt progression of early Covid-19 infection
MS Cohen - New England Journal of Medicine, 2021 - Mass Medical Soc
By the end of 2020, more than 19 million Americans had received the diagnosis of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 1 Although a substantial …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 1 Although a substantial …
[HTML][HTML] The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study
JR González-Juanatey, A Cordero… - International journal of …, 2022 - Elsevier
Background To evaluate the effectiveness of a cardiovascular polypill including aspirin,
ramipril and atorvastatin (CNIC-Polypill), on the incidence of recurrent major cardiovascular …
ramipril and atorvastatin (CNIC-Polypill), on the incidence of recurrent major cardiovascular …
Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials
S Rao, TJ Siddiqi, MS Khan, ED Michos… - Progress in …, 2022 - Elsevier
Prior studies have reported improvements in population-level risk factor burden and
cardiovascular disease (CVD) outcomes using polypills for CVD risk reduction. However, a …
cardiovascular disease (CVD) outcomes using polypills for CVD risk reduction. However, a …
Aspirin for secondary prevention of cardiovascular disease in 51 low-, middle-, and high-income countries
Importance Aspirin is an effective and low-cost option for reducing atherosclerotic
cardiovascular disease (CVD) events and improving mortality rates among individuals with …
cardiovascular disease (CVD) events and improving mortality rates among individuals with …
Uses of polypills for cardiovascular disease and evidence to date
Polypills have been approved in more than 30 countries, but worldwide experience with and
availability of polypills remain limited, unlike fixed-dose combinations in other diseases such …
availability of polypills remain limited, unlike fixed-dose combinations in other diseases such …